Guanethidine

Antihypertensive drug
  • C02CC02 (WHO) S01EX01 (WHO)
Pharmacokinetic dataElimination half-life1.5 daysIdentifiers
  • 2-[2-(azocan-1-yl)ethyl]guanidine
CAS Number
  • 645-43-2 checkY
PubChem CID
  • 3518
IUPHAR/BPS
  • 7194
DrugBank
  • DB01170 checkY
ChemSpider
  • 3398 checkY
UNII
  • 5UBY8Y002G
KEGG
  • D08030 ☒N
ChEBI
  • CHEBI:5557 checkY
ChEMBL
  • ChEMBL765 checkY
CompTox Dashboard (EPA)
  • DTXSID5023116 Edit this at Wikidata
ECHA InfoCard100.000.220 Edit this at WikidataChemical and physical dataFormulaC10H22N4Molar mass198.314 g·mol−13D model (JSmol)
  • Interactive image
  • N(=C(\N)N)\CCN1CCCCCCC1
InChI
  • InChI=1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13) checkY
  • Key:ACGDKVXYNVEAGU-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Guanethidine is an antihypertensive drug that reduces the release of catecholamines, such as norepinephrine. Guanethidine is transported across the sympathetic nerve membrane by the same mechanism that transports norepinephrine itself (NET, uptake 1), and uptake is essential for the drug's action. Once guanethidine has entered the nerve, it is concentrated in transmitter vesicles, where it replaces norepinephrine. It may also inhibit the release of granules by decreasing norepinephrine.

Medical uses

Guanethidine was once a mainstay for hypertension resistant to other agents, and was often used safely during pregnancy, but it is no longer used in the US due to lack of availability. It is still licensed in some countries, e.g., UK, for the rapid control of blood pressure in a hypertensive emergency.

Intravenous nerve block (Bier block) using guanethidine has been used to treat chronic pain caused by complex regional pain syndrome.[1]

Side effects

Side effects include postural and exercise hypotension, sexual dysfunction (delayed or retrograde ejaculation), and diarrhea.

Pharmacology

Guanethidine is transported by uptake 1 into the presynaptic terminal transported by norepinephrine transporter (NET). (In this it competes with norepinephrine so can potentiate exogenously applied norepinephrine.) It becomes concentrated in norepinephrine transmitter vesicles, replacing norepinephrine in these vesicles. This leads to a gradual depletion of norepinephrine stores in the nerve endings. Once inside the terminal it blocks the release of norepinephrine in response to arrival of an action potential. Spontaneous release is not affected.

References

  1. ^ Joyce PI, Rizzi D, Caló G, Rowbotham DJ, Lambert DG (November 2002). "The effect of guanethidine and local anesthetics on the electrically stimulated mouse vas deferens". Anesth. Analg. 95 (5): 1339–43. doi:10.1097/00000539-200211000-00045. hdl:11392/1198630. PMID 12401623. S2CID 12496389.
  • v
  • t
  • e
Sympatholytic (and closely related) antihypertensives (C02)
Sympatholytics
(antagonize α-adrenergic
vasoconstriction)
Central
α2-Adrenergic receptor agonists
Adrenergic release inhibitors
Imidazoline receptor agonists
Ganglion-blocking/nicotinic antagonists
Peripheral
Indirect
Monoamine oxidase inhibitors
VMAT inhibitors
Tyrosine hydroxylase inhibitors
Direct
α1-Adrenergic receptor blockers
Non-selective α-adrenergic receptor blockers
Other antagonists
Serotonin receptor antagonists
Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension)
  • v
  • t
  • e
Drugs used for glaucoma preparations and miosis (S01E)
Sympathomimetics
Parasympathomimetics
muscarinic
muscarinic/nicotinic
acetylcholinesterase inhibitors
Carbonic anhydrase inhibitors/
(sulfonamides)
Beta blocking agents
Prostaglandin analogues (F)
Other agents